KemPharm Inc, a leading pharmaceutical company, embodies certain values and a strong corporate philosophy. With a commitment to innovation and excellence, KemPharm is dedicated to delivering breakthrough medications that improve patients' lives. The company prioritizes scientific research and development, aiming to create novel and effective therapies to address unmet medical needs. KemPharm also values integrity, transparency, and ethical practices in all aspects of their operations. Through collaborations and strategic partnerships, they strive to advance their mission of advancing healthcare. Overall, KemPharm Inc is driven by a vision of providing cutting-edge pharmaceutical solutions and making a positive impact on the well-being of individuals worldwide.

KemPharm Inc is primarily present in the United States.

KemPharm Inc has achieved several significant milestones in their journey. The company successfully gained FDA approval for their proprietary product, Apadaz, a combination drug for acute pain management. Another milestone was the launch and commercialization of their ADHD medication, Azstarys, which received FDA approval for the treatment of attention deficit hyperactivity disorder. Additionally, KemPharm established collaborations with renowned pharmaceutical companies, enabling the development and commercialization of their innovative prodrug-based therapies. These achievements demonstrate KemPharm's commitment to advancing healthcare solutions and solidify their position as a leader in the pharmaceutical industry.

KemPharm Inc is a pharmaceutical company based in the United States. It was founded in 2006 and specializes in the discovery and development of innovative treatments for various medical conditions. KemPharm focuses on utilizing its proprietary Ligand Activated Therapy (LAT) platform technology to develop therapies that have improved safety and efficacy profiles. The company has a diverse pipeline of product candidates, including both clinical and preclinical stage assets, targeting numerous therapeutic areas. With a strong commitment to research and development, KemPharm is dedicated to delivering novel treatments to patients and making a positive impact in the healthcare industry.

The main competitors of KemPharm Inc in the market include pharmaceutical companies such as Purdue Pharma, Mallinckrodt Pharmaceuticals, and Pfizer.

KemPharm Inc is primarily active in the pharmaceutical industry.

The business model of KemPharm Inc revolves around developing and commercializing innovative medications to address unmet medical needs. As a specialty pharmaceutical company, KemPharm utilizes its proprietary Ligand Activated Therapy (LAT) platform technology to enhance existing drug products, resulting in improved efficacy, safety, and patient compliance. By leveraging this platform, KemPharm aims to provide novel treatment options in various therapeutic areas such as attention-deficit/hyperactivity disorder (ADHD), pain management, and other central nervous system disorders. Through strategic partnerships and collaborations, KemPharm strives to bring valuable medications to market and ultimately contribute to improving patient outcomes and quality of life.

Коефициентът на цена спрямо печалбата (КЦП) на Zevra Therapeutics е -3,05.

Коефициентът на цена към оборот (KUV) на Zevra Therapeutics е 15,34.

AlleAktien качественият резултат за Zevra Therapeutics е 4/10.

очаквана Zevra Therapeutics оборотът е 20,79 млн. USD.

очаквана Zevra Therapeutics печалба е -104,53 млн. USD.

KemPharm Inc. is a biopharmaceutical company that focuses on the development of new drugs, with a particular emphasis on pain therapy. The company utilizes its proprietary LAT (Ligand Activated Therapy) technology to develop modified pro-drugs that are converted into active molecules in the body. This concept allows for the development of medications with improved properties such as reduced toxicity, longer duration of action, and better bioavailability. In this article, we will describe KemPharm's business model and its various divisions and products. Business model: KemPharm concentrates on the development of innovative drugs, with a focus on pain therapy. The company utilizes its LAT technology to develop modified pro-drugs that exhibit improved pharmacological properties. KemPharm works closely with partners, including manufacturers and distributors, to bring its products to market. Divisions: KemPharm Inc. has several divisions focused on the development and commercialization of medications. These include: 1. Pain therapy: The company specializes primarily in pain therapy and has made significant advancements in the development of novel pain medications. Its flagship product is Apadaz, an oxycodone-based pain medication approved for acute pain treatment in the United States. The company has also developed KP415 and KP484, which are used for the treatment of attention deficit hyperactivity disorder (ADHD). 2. CNS disorders: KemPharm has also made advancements in the development of medications for the treatment of central nervous system (CNS) disorders. KP879 has been developed for the treatment of schizophrenia and bipolar disorders. 3. Narcolepsy: The company has expanded its portfolio to include medications for the treatment of narcolepsy. The main product, KP415, is a stimulant used for the treatment of both narcolepsy and ADHD. Products: KemPharm offers a wide range of products primarily used in pain and narcolepsy therapy. The key products include: 1. Apadaz: Apadaz is a pain medication containing oxycodone and acetaminophen. It is used for the treatment of acute pain and is approved in the US. 2. KP415: KP415 is a combination medication used for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD). The medication is a modified pro-drug containing dexmethylphenidate and has an extended duration of action. 3. KP484: KP484 is another modified pro-drug used for the treatment of ADHD. The medication contains hydrocodone and achieves its therapeutic effect through activation within the body. Conclusion: KemPharm Inc. is a biopharmaceutical company that focuses on the development of new drugs, with a particular emphasis on pain therapy. The company has made significant advancements in the development of unique medications and has achieved its goals. It offers a wide range of products and collaborates with partners to bring its products to market. Through its innovative solutions, KemPharm has gained an excellent reputation for quality, effectiveness, and safety.

Zevra Therapeutics разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Zevra Therapeutics в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Zevra Therapeutics е US4884452065.

WKN на Zevra Therapeutics е A2QLX7.

Тикерът на Zevra Therapeutics е ZVRA.

През последните 12 месеца Zevra Therapeutics изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Zevra Therapeutics да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Zevra Therapeutics в момента е .

Zevra Therapeutics изплаща дивидент на тримесечие. Той се разпределя в месеците .

Zevra Therapeutics платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Zevra Therapeutics се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Zevra Therapeutics на 12.12.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 12.12.2024 г..

Последното дивидентно плащане беше извършено на 12.12.2024 г..

През година 2023 Zevra Therapeutics изплати 0 USD под формата на дивиденти.

Дивидентите от Zevra Therapeutics се изплащат в USD.